Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA
- 1 February 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (3) , 977-982
- https://doi.org/10.1182/blood-2002-04-1273
Abstract
Current immunotherapeutic trials for patients with multiple myeloma (MM) focus on the idiotype (Id) as a tumor-specific antigen for active immunization. To bypass the need for the identification of shared MM-associated antigens and the characterization of possible immunogenic T-cell epitopes in a human leukocyte antigen (HLA) type–restricted manner, we focused on myeloma RNA transfection of dendritic cells (DCs). Total RNA encodes the whole antigen content of tumor cells, therefore allowing the transfected DCs to process and present the most relevant peptides and to induce a possible polyclonal cytotoxic T lymphocyte (CTL) response against different immunogenic antigens. We transfected monocyte-derived DCs with total RNA from the myeloma cell lines LP-1 and U266 by electroporation and investigated the potential of these DCs to induce myeloma-specific CTLs. We show that RNA-transfected DCs induce CTLs that lyse the LP-1 and U266 myeloma cells in an antigen-specific and major histocompatibility complex (MHC) class I–restricted manner, as demonstrated by cold-target inhibition and antibody-blocking studies. Interestingly, LP-1–specific CTLs showed no specificity for the idiotype. Consistent with studies demonstrating mucin 1 (MUC1) as a myeloma-associated antigen, we found MUC1 specificity of the CTLs induced with U266-derived RNA. As corresponding epitopes, we tested the described peptides M1.1 and M1.2 and found a striking fine specificity for M1.2, assuming a possible immunodominance of this peptide. This is the first report on the induction of myeloma-specific CTLs by RNA transfection of DCs.Keywords
This publication has 28 references indexed in Scilit:
- Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12Blood, 2002
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsBlood, 2002
- Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cellsBlood, 2001
- Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma proteinExperimental Hematology, 2001
- Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cellsProceedings of the National Academy of Sciences, 2000
- Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responsesIn vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing ceaInternational Journal of Cancer, 1999
- Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNANature Biotechnology, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.The Journal of Experimental Medicine, 1996
- Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their TumorsNew England Journal of Medicine, 1992